Phi’s PDCs target a biologically validated and widely expressed cancer antigen that remains under-explored – Chondroitin-Sulfate Proteoglycan-4 (CSPG4).
CSPG4 is very difficult to target effectively using conventional antibody-based technologies. Multiple solid and liquid tumours are characterized by high CSPG4 expression levels.
Deep Hematology/Oncology Drug Development & Commercialization Experience to advance strategic goals in the development of our pipeline of PDCs across multiple cancer indications.